We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Neurodegeneration – Products

A microarray result.
Product News

Sengenics Corporation Launches I-Ome Discovery To Advance Immune Biomarker Discovery and Development

Microarray-based solution enables deeper investigations of the humoral immune response in disease biology.
Protein structure.
Product News

Nanopore Technology Achieves Breakthrough in Protein Variant Detection

A team of scientists led by the University of Oxford have achieved a significant breakthrough in detecting modifications on protein structures.
Human cells.
Product News

Exploring Neurodegenerative Diseases in Microgravity

AMSBIO, is proud to announce its collaboration with WARR Space Labs, a student group from the Technical University of Munich (TUM).
Compendium

Applications and Innovations in Cell and Gene Therapy

Access this exclusive compendium for a selection of Technology Networks’ most popular content in this rapidly developing topic area including infographics, listicles, talk recordings and more.

Sygnature Discovery logo.
Product News

Sygnature Discovery Launches Its LPS In Vivo Model To Profile Early-Stage Anti-Inflammatory Drugs

Sygnature Discovery has established an in vivo LPS model of inflammation which can help understand life-limiting neuroinflammatory conditions like Parkinson’s disease, multiple sclerosis, Alzheimer’s disease, and traumatic brain injuries and identify new drug targets.
The Avacta logo
Product News

Avacta Announces Successful Completion of Fifth Dose Escalation in AVA6000 Phase I Clinical Study

Avacta Group plc has announced that the fifth dose escalation cohort in the ALS-6000-101 dose escalation Phase 1 clinical trial to evaluate the safety and tolerability of AVA6000 has been completed successfully.
A man and a woman stand next to the Neuro-Bio and Aptamer Group logos.
Product News

Aptamer Group and Neuro-Bio Partner To Develop an Alzheimer’s Disease Diagnostic Test

Aptamer Group plc and Neuro-Bio announce success in the development of Optimer binders to enable a lateral flow test for the early diagnosis of Alzheimer’s disease.
Samsara Therapeutics logo.
Product News

Samsara Therapeutics Parkinson’s drug receives funding boost from The Michael J. Fox Foundation

Samsara Therapeutics announced that it has received a grant from The Michael J. Fox Foundation for Parkinson’s Research to further its research into a promising Parkinson's disease drug.
Seer logo.
Product News

Seer Launches the Proteograph XT Assay Kit

Seer’s Proteograph XT pushes the boundaries of biological discovery by enabling rapid proteomics across a range of sample types and species with unprecedented resolution and scale.
The Samsara therapeutics logo
Product News

Samsara Therapeutics Unveils Promising Autophagy Drug Candidate

Samsara Therapeutics has announced the company’s autophagy-inducing candidate SAM001, the first agent of its class to enter clinical trials.
Advertisement